dc.contributor.author | YALÇIN, KENDAL | |
dc.contributor.author | Mueller, Tobias | |
dc.contributor.author | Haeussinger, Dieter | |
dc.contributor.author | Lammert, Frank | |
dc.contributor.author | AKARCA, ULUS SALİH | |
dc.contributor.author | Cakaloglu, Yilmaz | |
dc.contributor.author | GÜREL, SELİM | |
dc.contributor.author | Wranke, Anika | |
dc.contributor.author | Hardtke, Svenja | |
dc.contributor.author | Heidrich, Benjamin | |
dc.contributor.author | Dalekos, George | |
dc.contributor.author | Tabak, Fehmi | |
dc.contributor.author | Yurdaydin, Cihan | |
dc.contributor.author | Wedemeyer, Heiner | |
dc.contributor.author | Cornberg, Markus | |
dc.contributor.author | İDİLMAN, RAMAZAN | |
dc.contributor.author | Manns, Michael P. | |
dc.contributor.author | Woebse, Michael | |
dc.date.accessioned | 2021-03-02T17:33:15Z | |
dc.date.available | 2021-03-02T17:33:15Z | |
dc.identifier.citation | Wranke A., Hardtke S., Heidrich B., Dalekos G., YALÇIN K., Tabak F., GÜREL S., Cakaloglu Y., AKARCA U. S. , Lammert F., et al., "Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta", JOURNAL OF VIRAL HEPATITIS, 2020 | |
dc.identifier.issn | 1352-0504 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_1965c2ba-1211-462f-a0c6-73818c2c01a9 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/4025 | |
dc.identifier.uri | https://doi.org/10.1111/jvh.13366 | |
dc.description.abstract | Hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis. PEG-interferon alpha-2a (PEG-IFN alpha-2a) is the only effective treatment but its long-term clinical impact is unclear. The aim of this study was to investigate the long-term outcome after 48 weeks of pegylated interferon alpha-2a therapy. We performed a retrospective follow-up study of the Hep-Net-International-Delta-Hepatitis-Intervention-Study 1 (HIDIT-I trial). Patients had received 48 weeks of treatment with either PEG-IFN alpha-2a plus adefovir dipivoxil (ADV) (Group I), PEG-IFN alpha-2a alone (Group II) or adefovir dipivoxil alone (Group III). Liver-related complications were defined as liver-related death, liver transplantation, liver cancer and hepatic decompensation defined as development of Child-Pugh scores B or C or an increase in Model for End-stage Liver Disease (MELD) scores of five or more points in relation to baseline values. Patients were considered for further analysis when they were retreated with PEG-IFN alpha-2a. Follow-up data (at least 1 visit beyond post-treatment week 24) were available for 60 patients [Group I, (n = 19), Group II (n = 20), Group III (n = 21)]. Mean time of follow-up was 8.9 (1.6 - 13.4) years. 19 patients were retreated with IFN-based therapy: 42% (n = 8) in PEG-IFN alpha-2a arms and 58% (n = 11) in the adefovir only arm. Clinical complications on long-term follow-up occurred in 17 patients and were associated with nonresponse to therapy and baseline cirrhosis. The annual event-free survival rate in patients with cirrhosis vs noncirrhotic patients at year 5 and 10 was 70% vs 91% and 35% vs 76%. Long-term follow-up of a large randomized clinical trial suggests that off-treatment HDV RNA response to PEG-IFN alpha-2a treatment leads to improved clinical long-term outcome. | |
dc.language.iso | eng | |
dc.subject | Temel Tıp Bilimleri | |
dc.subject | İmmünoloji | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | VİROLOJİ | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Temel Bilimler | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Gastroenteroloji-(Hepatoloji) | |
dc.subject | İç Hastalıkları | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Viroloji | |
dc.subject | Mikrobiyoloji ve Klinik Mikrobiyoloji | |
dc.subject | GASTROENTEROLOJİ VE HEPATOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | BULAŞICI HASTALIKLAR | |
dc.title | Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta | |
dc.type | Makale | |
dc.relation.journal | JOURNAL OF VIRAL HEPATITIS | |
dc.contributor.department | Hannover Medical School , , | |
dc.contributor.firstauthorID | 2285766 | |